Faruqi & Faruqi, LLP Announces the Investigation of Tobira Therapeutics, Inc. (TBRA) Over the Proposed Sale of the Company to Allergan plc
Nadeem Faruqi, founding partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Tobira Therapeutics, Inc. (“Tobira” or the “Company”) (NASDAQ:TBRA) for potential breaches of fiduciary duties in connection with the sale of the Company to Allergan plc for approximately $1.695 billion.
The Company’s stockholders will only receive $28.35 per share, plus one non-transferrable contingent value right per share to receive one or more payments in cash of up to $49.84 per share total, contingent upon the achievement of certain milestones, for each share of Company common stock they own.
If you own common stock in Tobira and wish to obtain additional information and protect your investments free of charge, please fill out the form below or contact Nadeem Faruqi, Esq. either via e-mail at email@example.com or by telephone at (877) 247-4292 or (212) 983-9330. You may also contact Juan E. Monteverde, Esq. either via email at firstname.lastname@example.org or by telephone at (212) 971-1341.
Please tell us about yourself by completing the form below and we will provide you with additional
information at no cost to you on how to join the Class Action.
* The submission of this form does not create an attorney-client relationship.
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.